Previous studies demonstrate that although treatment with ipilimumab increases tumor-infiltrating T cells in PC patients, it also induces compensatory immune-inhibitory pathways, including PD-1/PD-L1, likely suppressing T-cell responses [86]. The gene discussed is CD274; the disease is pachyonychia congenita.